Study of Protein Arginine Methyltransferase 6 in Medulloblastoma by Grandinette, Sarah et al.
Purpose
Protein arginine methyltransferase 6 (PRMT6) was 
identified in a gain of function screen in which it 
enhanced proliferation of high REST expressing 
medulloblastoma cells. To better understand this 
interaction and its role in tumorigenesis, we studied 
the expression of PRMT6 in medulloblastoma and 
how knocking down this protein in vitro affects 
cancer cell viability. Potential therapeutic inhibitors 
of PRMT6 were tested for cytotoxicity in 
medulloblastoma cell lines.  
Methods
Published transcriptomic databases were mined for 
PRMT6 and REST expression and survival curves 
were generated. The brain sections of mice 
harboring patient derived xenografts (PDX) were 
stained with hematoxylin and eosin (H&E) to ensure 
tumors were present. Immunohistochemistry was 
performed to study the expression of PRMT6 in 
DAOY and DAOY high REST tumors. PRMT6 was 
knocked down in medulloblastoma cell lines using 
siRNA and cell viability was measured using MTT 
assays. qPCR will be done to confirm reduction of 
PRMT6 expression. In pre-clinical studies, MTT 
assays were performed to determine the IC50s of 
PRMT6 inhibitors (Licochalcone A, EPZ020411, and 
MS117) against a panel of medulloblastoma cell 
lines. 
Discussion
PRMT6 overexpression in cells with elevated REST 
expression enhanced proliferation and may 
contribute to tumorigenesis. To better understand the 
relationship between REST and PRMT6 in 
medulloblastoma, expression data was collected 
from two public patient databases and analyzed. 
REST and PRMT6 expression were elevated in both 
WNT and SHH driven medulloblastoma tumors. 
There was also a weak, positive correlation between 
REST and PRMT6 expression values. Co-elevation 
of REST and PRMT6 was associated with poor 
patient prognosis. PRMT6 expression will also be 
evaluated in a PDX mouse model of SHH 
medulloblastoma. H&E staining located tumors in the 
brains of mice xenografted with human 
medulloblastoma cell lines (DAOY and DAOY high 
REST). Experiments are ongoing to evaluate the 
expression of PRMT6 in tumors and the effect of 
PRMT6 knockdown on viability of SHH cell lines. 
MTT assays revealed the cytotoxicity of PRMT6 
inhibitors in SHH medulloblastoma cells in vitro. The 
UW426 cell line was more resistant to each inhibitor 
than DAOY, indicated by the greater IC50 values. 
DAOY REST-GFP was more sensitive to each 
inhibitor compared to DAOY GFP-GFP. Research is 
ongoing to understand whether PRMT6 is a driver of 
medulloblastoma and could be targeted for future 
therapies. 
Conclusions
We have identified a novel genetic interaction 
between REST and PRMT6 in medulloblastoma. If 
PRMT6 knockdown significantly decreases cell 
viability and parallels our findings from 
pharmacological studies with PRMT6 inhibitors, we 
will have provided the foundation for further 
mechanistic and pre-clinical studies focused on 
investigating the role of PRMT6 in REST-driven SHH 
medulloblastomas and the feasibility of targeting it for 
treatment. 
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Fig. 2 A. REST and PRMT6 expression were 
evaluated in the four molecular subgroups of 
medulloblastoma (WNT, SHH, Grp 3, and Grp 4) 
based on data collected from Cavalli and Pfister 
public databases. B. REST and PRMT6 expression 
Z-scores were compared to see if there was a 
correlation. C. The survival curve shows the 
probability of survival of patients with different levels 
of REST and PRMT6 expression in tumors. (3,4)
Fig. 3 H&E staining of A. wild type mouse 
cerebellum, B. DAOY xenograft tumors, and C.
DAOY high REST xenograft tumors.
Results
Table 1 Half maximum inhibitory concentrations of 
PRMT6 inhibitors tested in SHH cell lines where GG and 
RG represent DAOY GFP-GFP and REST-GFP
respectively. 
IC50 Values (μM)
UW426   DAOY   GG      RG   
Licochalcone A 36.15    21.98   25.66   14.88
EPZ020411 87.68    21.55   71.83   25.47
MS117 54.01    42.65   74.32   47.00
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Background
Medulloblastoma is the most common malignant 
brain tumor in children and a major cause of cancer 
related childhood mortality. Current treatments have 
drastic side effects that can last throughout a 
patient’s lifetime. The search for new treatments 
requires a better understanding of medulloblastoma 
biology. The sonic hedgehog (SHH) subgroup of 
medulloblastomas overexpress RE1-silencing 
transcription factor (REST), which represses 
neuronal differentiation genes and drives 
tumorigenesis. REST elevation in cerebellar 
granule progenitor cells (CGNPs) increased 
proliferation and decreased telomere length (1). 
The latter is a trigger for senescence and 
apoptosis; however, these cells escape both 
processes. To better understand these 
mechanisms, we performed a gain of function 
screen with a library of epigenes. Protein arginine 
methyltransferase 6 (PRMT6) was identified as a 
high-priority REST-interacting protein. PRMT6 is 
known to regulate the expression of genes involved 
in senescence (2). The availability of PRMT6 
specific inhibitors for evaluation in pre-clinical 
studies was an added criterion for our focus on 
PRMT6. Our hypothesis is that PRMT6 prevents 
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Fig. 1 After 18 days, RESTTG progenitor cells 
overexpressing PRMT6 have enhanced proliferation 
compared to WT. 
WT RESTTG
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Fig. 4 MTT assay data for SHH cell lines (UW426 




Fig. 5 MTT assay data for 
DAOY cell lines GFP-GFP 
and REST-GFP treated 
with three PRMT6 
inhibitors.
